top of page
vinnytsia-ukraine-december-28-2017-offset-printing-process-ready-newspaper-print-mashine.j

DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.

EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

PUBLICATIONS

Publications

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.

arrow&v
arrow&v
arrow&v
arrow&v

STUDY

OFFICIAL TITLE

DISEASE

JOURNAL/
CONGRESS

YEAR

DOWNLOAD

Publications

DEBBRAH

Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial

BREAST

(Journal) Neuro-Oncology

2023

DEBBRAH
Publications

I3LUNG

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

LUNG

(Journal) Clinical Lung Cancer

2023

I3LUNG
Publications

PHERGAIN

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) 

BREAST

ASCO

2023

PHERGAIN
Publications

ORPHEUS

A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS

PENIS

ASCO

2023

ORPHEUS
Publications

PARSIFAL

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial 

BREAST

(Journal) The Oncologist

2023

PARSIFAL
Publications

BIOPER

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

BREAST

(Journal) Clinical Cancer Research

2023

BIOPER
Publications

PALMIRA

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial 

BREAST

ASCO

2023

PALMIRA
Publications

PRIMED

A phase 2 trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED Study 

BREAST

ESMO Breast

2023

PRIMED
Publications

DEBBRAH

Trastuzumab Deruxtecan in Patients with Unstable Central Nervous System Involvement from HER2-low advanced Breast Cancer: The DEBBRAH Trial

BREAST

SABCS

2022

DEBBRAH
Publications

CALADRIO

Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO

BREAST

ESMO Breast

2022

CALADRIO
Publications

PECATI

A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

BREAST

ESMO

2022

PECATI
Publications

REVERT

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

BREAST

(Journal) Cancers

2022

REVERT
Publications

Other MEDSIR related articles

home_fondo_cuadritos2.jpg
"
WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.
bottom of page